BC066028 Inhibitors
BC066028, a protein intricately involved in cellular processes, functions as a key player in protein regulation and cellular homeostasis. Its primary role encompasses diverse activities, ranging from protein folding and stability to transcriptional control, making it a pivotal component of cellular machinery. BC066028 is notably associated with various molecular interactions and signaling pathways, reflecting its multifaceted involvement in fundamental cellular processes. The general mechanisms of inhibition for BC066028 inhibitors revolve around targeted disruptions of specific molecular interactions or signaling pathways. Direct inhibitors, such as Geldanamycin and JQ1, act by directly interfering with BC066028's interactions with Hsp90 and bromodomains, respectively. This disruption leads to destabilization or alteration of BC066028, affecting its functions in protein folding and gene regulation. Additionally, indirect inhibitors like MG-132 and SB-216763 modulate cellular processes related to protein turnover and kinase signaling, indirectly influencing BC066028 by altering its cellular environment.
Furthermore, agents like Nutlin-3 and Trichostatin A indirectly affect BC066028 by disrupting interactions with MDM2 and modulating histone acetylation, respectively. These actions illustrate the interconnectedness of BC066028 with various cellular components and epigenetic modifications. The indirect inhibitors, including BAY 11-7082 and Pifithrin-α, influence BC066028-associated pathways such as NF-κB and p53, demonstrating the intricate cross-talk between BC066028 and signaling cascades. The diverse mechanisms of inhibition emphasize the complexity of BC066028-mediated cellular processes and the potential for targeted intervention in various pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin, an Hsp90 inhibitor, directly targets BC066028 by disrupting its interaction with Hsp90. BC066028 is dependent on Hsp90 for stability, and Geldanamycin's inhibition destabilizes BC066028, leading to its degradation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
(+/-)-JQ1, a BET bromodomain inhibitor, directly inhibits BC066028 by disrupting bromodomain interactions. BC066028 associates with chromatin, and JQ1's action on bromodomains interferes with this binding, directly affecting BC066028-mediated gene regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132, a proteasome inhibitor, indirectly influences BC066028 by preventing proteasomal degradation. BC066028 turnover is regulated by the proteasome, and MG-132's action on the proteasome indirectly stabilizes BC066028, influencing its cellular functions related to protein degradation and turnover. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB-216763, a GSK-3 inhibitor, indirectly inhibits BC066028 by disrupting the GSK-3 signaling pathway. BC066028 interacts with GSK-3, and SB-216763's action on GSK-3 interferes with this interaction, indirectly influencing BC066028-associated cellular processes and downstream signaling events. | ||||||
(–)-Nutlin-3 | 675576-98-4 | sc-222086 sc-222086A | 1 mg 5 mg | $120.00 $215.00 | 2 | |
(–)-Nutlin-3, a p53/MDM2 inhibitor, indirectly influences BC066028 by disrupting the p53-MDM2 interaction. BC066028 interacts with MDM2, and Nutlin-3's action on this interaction indirectly impacts BC066028 through alterations in MDM2-mediated cellular processes. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, an HDAC inhibitor, indirectly inhibits BC066028 by modulating histone acetylation. BC066028 associates with chromatin, and Trichostatin A's action on HDACs alters chromatin structure, indirectly influencing BC066028-mediated gene regulation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly influences BC066028 by disrupting NF-κB signaling. BC066028 interacts with components of the NF-κB pathway, and BAY 11-7082's action on NF-κB interferes with this interaction, indirectly impacting BC066028-associated cellular processes and downstream signaling events. | ||||||
Pifithrin-α hydrobromide | 63208-82-2 | sc-45050 sc-45050A | 5 mg 25 mg | $118.00 $287.00 | 36 | |
Pifithrin-α(HBr), a p53 inhibitor, indirectly inhibits BC066028 by disrupting the p53 pathway. BC066028 interacts with p53, and Pifithrin-α(HBr)'s action on p53 interferes with this interaction, indirectly influencing BC066028-associated cellular processes and downstream signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences BC066028 by disrupting the PI3K/AKT pathway. BC066028 interacts with AKT, and LY294002's action on PI3K interferes with this interaction, indirectly affecting BC066028-associated cellular processes and downstream signaling events. The interconnected nature of kinase pathways highlights the indirect modulation of BC066028 by LY294002. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin, a DNA crosslinking agent, indirectly influences BC066028 by inducing DNA damage. BC066028 participates in DNA repair, and Cisplatin's impact on DNA structure indirectly challenges BC066028's role in maintaining genomic stability. | ||||||